Bain Capital Life Sciences Investors LLC Has $275.48 Million Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Bain Capital Life Sciences Investors LLC boosted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,719,110 shares of the company's stock after acquiring an additional 245,197 shares during the quarter. NewAmsterdam Pharma accounts for about 32.4% of Bain Capital Life Sciences Investors LLC's investment portfolio, making the stock its biggest position. Bain Capital Life Sciences Investors LLC owned about 11.60% of NewAmsterdam Pharma worth $275,481,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in NewAmsterdam Pharma by 176.9% during the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after buying an additional 14,280 shares during the last quarter. State Street Corp grew its holdings in shares of NewAmsterdam Pharma by 168.7% during the third quarter. State Street Corp now owns 37,915 shares of the company's stock worth $629,000 after purchasing an additional 23,805 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of NewAmsterdam Pharma in the fourth quarter valued at $8,907,000. Geode Capital Management LLC raised its holdings in shares of NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after buying an additional 1,399 shares during the last quarter. Finally, Swiss National Bank lifted its position in NewAmsterdam Pharma by 105.1% during the 4th quarter. Swiss National Bank now owns 72,000 shares of the company's stock worth $1,850,000 after buying an additional 36,900 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded up $0.05 during trading on Friday, hitting $17.52. 345,323 shares of the company were exchanged, compared to its average volume of 592,501. The firm has a market capitalization of $1.92 billion, a P/E ratio of -6.74 and a beta of -0.01. The firm's fifty day moving average price is $19.61 and its 200 day moving average price is $21.19. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million. As a group, equities research analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

NAMS has been the subject of a number of research analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank upped their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, April 8th. HC Wainwright restated a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Finally, UBS Group set a $41.00 price target on NewAmsterdam Pharma in a report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma has a consensus rating of "Buy" and an average target price of $43.33.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares of the company's stock, valued at approximately $305,550. This trade represents a 90.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, with a total value of $25,526.15. Following the transaction, the director now owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.